Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S6W-06808 · Session 6

How the site-specific brain tumour research funding that is provided through the Chief Scientist Office is allocated between the National C…

Answered Asked by Beatrice Wishart LD Lodged 18 Feb 2022

The question

To ask the Scottish Government how the site-specific brain tumour research funding that is provided through the Chief Scientist Office is allocated between the National Cancer Research Institute (NCRI) Common Scientific Outline categories of (a) biology, (b) aetiology, (c) prevention, (d) early detection, diagnosis and prognosis, (e) treatment and (f) cancer control, survivorship and outcomes research.

The answer

Answered by Maree Todd on 2 Mar 2022 · 12 days after it was lodged, on time

A search of the National Cancer Research Institute (NCRI) Cancer Research Database (CaRD) carried out by NCRI at the request of the Chief Scientist Office (CSO) showed the following allocation for CSO funded site-specific brain tumour research by Common Scientific Outline category
Category 1. Biology
- total 4.1% /£22,275
Sub-category 1.5: Resources and Infrastructure
- £22,275
Category 2. Aetiology
0
Category 3. Prevention
0
Category 4. Early Detection, Diagnosis and Prognosis
- total 59.9% /£325,022
Sub-category 4.1: Technology Development and/or Marker Discovery
- £67,767
Sub-category 4.2: Technology and/or Marker Evaluation
- £134,305
Sub-category 4.4: Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis
- £122,950
Category 5. Treatment
- total 35.6% / £192,875
Sub-category 5.3: Systemic Therapies
- Discovery and Development
- £13,928
Sub-category 5.4: Systemic Therapies
- Clinical Applications
- £48,685
Sub-category 5.7: Resources and Infrastructure Related to Treatment and the Prevention of Recurrence £130,262
Category 6. Cancer Control, Survivorship, and Outcomes Research
- total 0.4% / £2,195
Sub-category 6.2: Surveillance
- £2,195
In the June 2021 round of the CSO Translational Clinical Studies Committee, the following research project was funded:
Developing representative models of the blood-tumour barrier to enhance drug development for Glioblastoma
Lead Investigator: Prof. Anthony Chalmers / Univeristy of Glasgow / £296,864 TCS2105.pdf (scot.nhs.uk)
This project will be categorised at the next update of the NCRI CaRD (scheduled Summer 2022)

In the Official Report

No contribution in the Official Report cites S6W-06808 by reference.